No argument with that. The completed CLBP phase 3 trial has already guided some precision, as we agree. And it's more than possible RWE could add further refinement to identifying likely responders when data accumulates after approval. Another non-NGS example which gives us great joy is the huge advantage patients with elevated CRP enjoy from Revascor. No genetic analysis required there, just a simple blood test.
No argument with that. The completed CLBP phase 3 trial has...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.020(1.95%) |
Mkt cap ! $1.193B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.07 | $1.02 | $7.487M | 7.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 39700 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 86509 | 6 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
0.020 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| $1.02 | $1.07 | $1.02 | 1379563 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| MSB (ASX) Chart |